US FDA Office Of New Drugs Likely To Be Headed By Deputy Director Stein
Executive Summary
Peter Stein is a familiar face within OND and has been working alongside CDER Director Janet Woodcock on the proposed “modernization” of OND. As a previous recruit from outside FDA, Stein has had time to make the key connections and adjustments to working inside government.
You may also be interested in...
Peter Stein Takes Short Path To Director Of US FDA Drug Office
An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."
Four Rules For Being A Consistent US FDA Reviewer From Peter Stein
Amid concerns Office of New Drugs reorganization will result in sponsors receiving conflicting advice, new director offers several items already contemplated to prevent such problems.
CDER Recruitment Wins Begin Outnumbering Losses
US FDA's drug center has been hiring more employees than it has lost over the last few months and hopes the Office of New Drugs reorganization will help retention.